Design of epigallocatechin gallate loaded PLGA/PF127 nanoparticles and their effect upon an oxidative stress model

Hoyos-Ceballos, Gina P.; Sánchez-Giraldo, Vanesa; Mendivil-Perez, Miguel; Jiménez-Del-Río, Marlene; Sierra-Garcia, Ligia; Vélez-Pardo, Carlos; López-Osorio, Betty L.

doi:10.1016/j.jddst.2018.09.010

Cited by 11 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A key question then arises: can EGCG be translated to the clinic in FAD PSEN1 E280A patients [ 60 ]? Our present results and previous experimental approaches with EGCG loaded in nanoparticles (e.g., [ 61 , 62 , 63 ]) encourage its use in the treatment of FAD patients. Although the EGCG dose levels and administration route remain to be established, the EGCG nonetheless might be a promising therapeutic candidate for FAD.…”

Section: Discussionsupporting

confidence: 78%

(−)-Epigallocatechin-3-Gallate Diminishes Intra-and Extracellular Amyloid-Induced Cytotoxic Effects on Cholinergic-like Neurons from Familial Alzheimer’s Disease PSEN1 E280A

et al. 2021

Self Cite

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a complex neurodegenerative disease characterized by functional disruption, death of cholinergic neurons (ChNs) because of intracellular and extracellular Aβ aggregates, and hyperphosphorylation of protein TAU (p-TAU). To date, there are no efficient therapies against AD. Therefore, new therapies for its treatment are in need. The goal of this investigation was to evaluate the effect of the polyphenol epigallocatechin-3-gallate (EGCG) on cholinergic-like neurons (ChLNs) bearing the mutation E280A in PRESENILIN 1 (PSEN1 E280A). To this aim, wild-type (WT) and PSEN1 E280A ChLNs were exposed to EGCG (5–50 μM) for 4 days. Untreated or treated neurons were assessed for biochemical and functional analysis. We found that EGCG (50 μM) significantly inhibited the aggregation of (i)sAPPβf, blocked p-TAU, increased ∆Ψm, decreased oxidation of DJ-1 at residue Cys106-SH, and inhibited the activation of transcription factor c-JUN and P53, PUMA, and CASPASE-3 in mutant ChLNs compared to WT. Although EGCG did not reduce (e)Aβ42, the polyphenol reversed Ca2+ influx dysregulation as a response to acetylcholine (ACh) stimuli in PSEN1 E280A ChLNs, inhibited the activation of transcription factor NF-κB, and reduced the secretion of pro-inflammatory IL-6 in wild-type astrocyte-like cells (ALCs) when exposed to mutant ChLNs culture supernatant. Taken together, our findings suggest that the EGCG might be a promising therapeutic approach for the treatment of FAD.

show abstract

Section: Discussionsupporting

confidence: 78%

(−)-Epigallocatechin-3-Gallate Diminishes Intra-and Extracellular Amyloid-Induced Cytotoxic Effects on Cholinergic-like Neurons from Familial Alzheimer’s Disease PSEN1 E280A

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…A very promising targeting ligand for the delivery of nanomedicines into the brain is Angiopep-2 (Ang-2), a 19 amino acid peptide (TFFYGGSRGKRNNFKTEEY-OH) which binds the low-density lipoprotein receptor-related protein 1 (LRP1), which is widely expressed throughout the central nervous Poly(lactic-co-glycolic acid) of molecular weight 24-38 kDa (PLGA 50:50) and Pluronic F127 ® were purchased from Sigma-Aldrich (Milan, Italy). The PLGA-b-PEG copolymer was previously obtained through the modification of PLGA with mPEG-NH 2 (MW: 5000 Da) [22]. The PLGA (Resomer 503 H) derivatized with the fluorophore Cy5 was obtained by the Laboratory of Nanomedicine and Pharmaceutical Technology of the University of Modena and Reggio Emilia (Modena, Italy) as previously reported [25].…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, literature extensively reported its ability to encapsulate, protect, and deliver a wide range of bioactive compounds (small molecules, proteins, enzymes, etc.) [20][21][22]. However, only a few studies indicated that PLGA-based nanoparticles modified with Ang-2 could be a promising active brain-targeting drug delivery system [13,14,18,23,24].…”

mentioning

confidence: 99%

PLGA-PEG-ANG-2 Nanoparticles for Blood–Brain Barrier Crossing: Proof-of-Concept Study

et al. 2020

Self Cite

View full text Add to dashboard Cite

The treatment of diseases that affect the central nervous system (CNS) represents a great research challenge due to the restriction imposed by the blood–brain barrier (BBB) to allow the passage of drugs into the brain. However, the use of modified nanomedicines engineered with different ligands that can be recognized by receptors expressed in the BBB offers a favorable alternative for this purpose. In this work, a BBB-penetrating peptide, angiopep-2 (Ang–2), was conjugated to poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles through pre- and post-formulation strategies. Then, their ability to cross the BBB was qualitatively assessed on an animal model. Proof-of-concept studies with fluorescent and confocal microscopy studies highlighted that the brain-targeted PLGA nanoparticles were able to cross the BBB and accumulated in neuronal cells, thus showing a promising brain drug delivery system.

show abstract

“…Hoyos-Ceballos et al prepared EGCG loaded PLGA/PF127 nanoparticle, nearly 100 nm in size, with an encapsulation efficiency of 86%. The finding on the oxidative stress model showed rotenone-induced ROS generation prevention and mitochondrial membrane potential loss, with DNA fragmentation in the nerve cells [ 154 ]. Hence, all observations supported that EGCG had great therapeutic efficacy toward AD s .…”

Section: Nanocarrier Containing Natural Product Used To Combat Alzheimer's Diseasementioning

confidence: 99%

Therapeutic Potential of Phytoconstituents in Management of Alzheimer’s Disease

Singh

Nand

Maurya

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Since primitive times, herbs have been extensively used in conventional remedies for boosting cognitive impairment and age-associated memory loss. It is mentioned that medicinal plants have a variety of dynamic components, and they have become a prominent choice for synthetic medications for the care of cognitive and associated disorders. Herbal remedies have played a major role in the progression of medicine, and many advanced drugs have already been developed. Many studies have endorsed practicing herbal remedies with phytoconstituents, for healing Alzheimer’s disease (AD). All the information in this article was collated from selected research papers from online scientific databases, such as PubMed, Web of Science, and Scopus. The aim of this article is to convey the potential of herbal remedies for the prospect management of Alzheimer’s and related diseases. Herbal remedies may be useful in the discovery and advancement of drugs, thus extending new leads for neurodegenerative diseases such as AD. Nanocarriers play a significant role in delivering herbal medicaments to a specific target. Therefore, many drugs have been described for the management of age-linked complaints such as dementia, AD, and the like. Several phytochemicals are capable of managing AD, but their therapeutic claims are restricted due to their lower solubility and metabolism. These limitations of natural therapeutics can be overcome by using a targeted nanocarrier system. This article will provide the primitive remedies as well as the development of herbal remedies for AD management.

show abstract

Design of epigallocatechin gallate loaded PLGA/PF127 nanoparticles and their effect upon an oxidative stress model

Cited by 11 publications

References 42 publications

(−)-Epigallocatechin-3-Gallate Diminishes Intra-and Extracellular Amyloid-Induced Cytotoxic Effects on Cholinergic-like Neurons from Familial Alzheimer’s Disease PSEN1 E280A

(−)-Epigallocatechin-3-Gallate Diminishes Intra-and Extracellular Amyloid-Induced Cytotoxic Effects on Cholinergic-like Neurons from Familial Alzheimer’s Disease PSEN1 E280A

PLGA-PEG-ANG-2 Nanoparticles for Blood–Brain Barrier Crossing: Proof-of-Concept Study

Therapeutic Potential of Phytoconstituents in Management of Alzheimer’s Disease

Contact Info

Product

Resources

About